A tidal wave of promotional letters on Amarantus BioSciences Inc (OTC:AMBS) hit the e-mails of investors late last night. Five promoters among which Whispers From Wallstreet and market Caliber joined their forces to advertise the biotechnology company.
Â
Unfortunately none of the newsletters had informative enough disclaimer as to indicate the compensation and the third parties in the campaign. Hopefully, the promoters will provide this information in their further updates on the company.
AMBS is a biotechnology company focusing on the research and development of first class disease-modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide specter of maladies. [BANNER]
In its current form AMBS has been on the public market for only two months now. On May 25, 2011, the public online retailing company Jumpkicks Inc merged with Amarantus Therapeutics and as a result AMBS has ceased its previous business plan and delved into the biotech industry.
For this reason, the financial reports of AMBS filed with the SEC pertain to the former public company Jumpkicks Inc. Therefore, it is yet to see how AMBS will perform on the market. The started promotional campaign may bring more attention to AMBS stock but it is too early to predict how this will affect the company’s share value.
